excellent health. obstacles protect orders measures public to had despite other Thank an posed at home Corcept you, commercial quarter, Charlie. by and stay
them patients medical team Korlym Cushing's sure cortisol specialty COVID-XX liaisons, got operations advocates, for science serious specialist, the suffer patients Cushing's pharmacy likely infections, clinical high syndrome patient and also especially cause medication. suppresses Our activity of mortality made are COVID-XX. putting They immune times at four Excess risk Patients leading to their exceptionally experience risk to severe with more another and an in morbidity more are syndrome. with likely system. patients to COVID-XX. with to poses five taking blood clots,
medical pandemic now. treated, rest year. be patients The with to it always how the it and Korlym. for poses risks will the the COVID-XX important the At difficult to make local imposed demand syndrome affect and hard likely especially and to state individual optimally hospitals diagnosed same with It's Cushing's commercial by physicians time with governments, practices syndrome our that of work it's patients is are increase for in important predict very restrictions business person. Cushing's While to
closed. diagnosing patients use the when imaging physicians optimum and an to titrating with Korlym laboratories are centers of of Some and syndrome Cushing's dose
hesitant patients more leave which difficult make to dose to following are are patients for the These reduce likely doctor. to patients Korlym introduced visit rate physicians at to it to titration. homes Many are factors even their and the monitor new
endemic. physicians as in patients a COVID-XX is which However, to world and adapt
of the our revenue the evolve our related how these do, As revenue, million, guidance may that million based and months. of strong and they results our our factors other beginning over are estimate first We diminish. to quarter pandemic factors $XXX will coming best eyes reaffirm XXXX of the determine to $XXX on impact
of trial as Cushing's patients are you trial a planned Phase Korlym known successor relacorilant, to conducting GRACE. many The As with III as our for treatment know, syndrome. is we of a
Our to off endpoints Cushing hypertension efficacy trial findings patients safety and relacorilant's pernicious which Phase to control of most glucose without is GRACE significant in II as positive and for important in syndrome's of confirm well secondary the target effects. Korlym exhibit goal an manifestations, meaningful improvements as instances
slash can found be relacorilant's poster investors website. the our events at presentation Our tab past of II Phase results of
medical We major relacorilant commercial will and a believe advance. constitute
GR receptor, for the label Cushing's significant effective time affinity Phase carry thickening for Korlym is medication safety the not by requires termination makes it's points data one a II syndrome. Korlym's it at Korlym's the are progesterone bleeding Unfortunately, of in pregnancy. benefits. patients a to relacorilant glucocorticoid which to with in Korlym's FDA selected comparable also required to treatment the causes the GR. endometrial warning, and for receptor, and for promises black-box It for of women While most to offer serious age same Korlym's regardless many the vaginal binds pivotal trial, highly short, efficacy
progesterone a different discontinuation pivotal Unlike It cause Korlym GR selective a by side abortion experienced with medication. not receptor. serious thickening affinity low trial, potentially vaginal Korlym's of cause is as patients the mechanism does that pill. or manageable, patients and of is taking bleeding. the modulator Korlym, but By endometrial effect hypokalemia, in causes for relacorilant was the a not It XX% potassium leading in no
saw pace avoid. or and in planned Phase strongly opening we the I prefer the of last These relacorilant's would addition, COVID-XX few and of our has pandemic The of hypokalemia effects drug XX trial the in sites. side In instance to II enrollment no clinical slowed patients GRACE of induced studies. Phase the physicians delay are
in remaining ease, open XXXX. our to restrictions As health We plan the we expect fall. now and submit to resume NDA enrollment quarter of public full this to our second sites
patients months, The randomized caused with improvements hypertension. syndrome It Cushing's by enrollment Europe. Participants will the double of etiology adenoma This quarter, will G-R-A-D-I-E-N-T. patients will patients whose blind either being and or in is placebo-controlled trial six in the XX study in called United hyperplasia. for is we placebo or primary GRADIENT in metabolism syndrome. the an planned endpoints adrenal III GRADIENT, of this Phase Cushing study States first has be sites of and at start glucose a relacorilant relacorilant adrenal with receive XXX
in investigators for participate the It required GRADIENT. GRACE development hypercortisolism. the with of relacorilant's to of is of our a patients GRADIENT treat also Many not part of part is will NDA. in relacorilant investment
and syndrome. the Cushing this of simply improve to Our goal treatment help type is inform with patients of
also is available of publications presentation the Journal supplemental tab at poster the design our available Endocrine April, An GRADIENTs May Our in slash of the is pipeline of and Society. of abstract issue research website. the
I three may to will tumors death cortisol cell now turn GR. examining benefit our that the cause apoptosis, Cortisol potential mechanisms suppresses program, patients. modulation is programmed which and the is activity to meant express chemotherapy which oncology by
chemotherapy our to thereby its We killing anti-apoptotic chemotherapy correlate cortisol are cancer will will testing adding blend full cortisol's selected achieve whether modulator to effect, potential. allowing
data from presented results reported goal label the Our striking relacorilant we of last to in we is ASCO drug nab-paclitaxel, Abraxane. trial our Celgene's confirm chemotherapy open plus year, where
of patients of XX of durable In growing shrank catching. exhibited with including benefit tumors ovarian weeks either progressed control, these and for disease shrinkage therapy with Taxanes. cancer eye cancer XX for patients advanced some or One cancer hit cancer have XX during tumors our seven exhibited pancreatic with XX duration with ceased patients patients of Two all their for weeks. with prior in patient XX pancreas patients tumor The than in tumor study meaning or longer. lines of weeks. metastatic shrinkage ovarian therapy, was The multiple more five metastatic
slash available investors is presentation website. of our events tab past poster results these Our of at the
duration United Last to at ovarian II with in Phase primary year, relacorilant of and Europe. expect patients with patients results we arising nab-paclitaxel endpoint study XX trial COVID-XX plus the continue half and States endpoints survival next to cancer, enrollment began metastatic sites XXX controlled The during with in free of of planned from survival progression challenges a pandemic, year. of we including benefit. Despite this is the of first secondary overall the
combination with pancreatic will a in prognosis. Phase dire relacorilant nab-paclitaxel, a This called with in cancer, quarter will of be RELIANT, III trial we This start patients a metastatic disease R-E-L-I-A-N-T. trial with
RELIANT XX cortisol resist effect for will sufficiently States. which cancer believe also primary from tumor an killing could bolstering with support accelerated patients. cancer be patients plus in cells. We of conducted at and interim suppresses analysis their trial will United the relacorilant checkpoint modulation endpoint the disorders on RELIANT helps benefit open sites in being nab-paclitaxel, as be It It to data patients is first the label positive the to XX the approval. by objective results attributes of In ability often criteria. however, immuno may immune immune Cortisol rate cortisol XX prevent, plan perform arthritis. destroy patients blunts such response This recognize assessed activity receive natural We an the immunosuppressant. therapeutic agents to beneficial. the is response the system rheumatoid with autoimmune body's inhibitors. such example, also as by
patients cancer. PD-X KEYTRUDA these relacorilant their are modulation can Next trial in an have Ib quarter, in patients syndrome, or adrenal cortisol produce starting metastatic cortical plus tumors inhibitor of the XX open also cortisol, with which we Phase drug Merck's treat. Cushing's label Because checkpoint pembrolizumab unresectable
can, Cushing's its the syndrome what these specifically treating activity. achieve examine maximum trial reducing cortisol to patients, Our excess addition of a immunotherapy effect immunosuppressive by effects in in help relacorilant
activity Finally, when researchers the Xtandi growth cortisol cancer by tumors, with as of University exposed drug modulation colonies medications Pfizer's standard enzalutamide that have cortisol patients stimulated Chicago prostate receptor are may are recently, is Kettering stimulates resistant castration is at growth More androgen of benefit such at prostate in why GR. Sloan antagonism the which the cancer. therapy. with to of enzalutamide, shown cells prostate Androgen
tumor receptor that is route. with regimen androgen this hypothesis block combining modulator will Our escape a a cortisol an antagonist
a in II exicorilant castration trial. end By expect modulator we to models this the select resistant is of with of forward dose enzalutamide to the potent animal in year, cortisol optimum controlled cancer. combination selective prostate Our in of Phase exicorilant bring
dose In of conducted the plus a relacorilant at Chicago. by finding investigators addition, trial University enzalutamide of is being
our of conclude I metabolic update disorders. with an in will program
one of you cortisol medications these are As disorders cost we on death rapid olanzapine antipsychotic causes nearly for in NASH. lipid bargain, are weight bipolar disorder. the serious as to steatohepatitis and including miricorilant suicide who as abnormalities patients them. disease such and such but cause Heart know, Unfortunately, of takes treat treatment modulator dangerous a acquiring to patients selective non-alcoholic anti-psychotic or our terrible and of everyone forced make in taking of weight many Millions and medications. of induced developing metabolic the gain are disease, stroke Patients not gain diseases treat rely another. leading at schizophrenia, drugs the
olanzapine blind We up weight mifipristone by can do reduced trials to two which taking double placebo-controlled in Risperidone. healthy subjects caused in or gain
widely journals Our in fashion has for board results disqualify pill, Therapy in further modulator indication not this as advance could Miricorilant mifipristone's can a energy be disorders. and published mifipristone of is we the is common quality for were the could Advances with Obesity. the distributed. PR. because no for selective Unfortunately, it be because cortisol the advanced It not abortion treatment it if a approved, and
And our gain In received in miricorilant either the subjects and days. healthy than humans. gained or weight XXX Participants of trial, models subjects, animal weight antipsychotic in mifipristone blind active human in double healthy in antipsychotic of who miricorilant now demonstrated effective placebo Ib for olanzapine indused placebo-controlled who received completed first is Phase reducing that those induced in received more less PhaseIb miricorilant study XX placebo. is part XX our Miricorilant has weight gain. and
patients received protective liver of enzymes, addition, who less in markers the liver. that liver miricorilant increased damage, in suggesting effects has In miricorilant,
XX XXX part the placebo miricorilant In our confirm days. at the The results study, subjects the from milligrams findings and or of second for received receiving olanzapine patients of healthy part first trial our XX liver less other No sharply elevated of and miricorilant who placebo. subjects effects in is miricorilant. were dose enzymes side received weight either lower gained with and olanzapine than seen with triglycerides commonly seen had less in even
this plan we miricorilant of our results to published Ib future The higher be study In year. fact, exposures full later studies. will levels considerably of investigate Phase in
dose antipsychotic GRATITUDE recent either to Phase XX II States. for induced approximately In is placebo study weight gain placebo-controlled miricorilant Our be XXX centers weeks. called with in double of XX at their GRATITUDE patients will medication the continue to this United schizophrenia established milligrams or progress. of blind across of XXX miricorilant receive in trial will antipsychotic conducted reverse,
antipsychotic suspended trial trial, with pandemic standing COVID-XX weight in effectively long to in delay are resume placebo-controlled the we year-end, public will induced Phase confident enrollment as has health There's new plans restrictions While been II gain. blind no this our enrollment start by ease. double patients in a
reached believe be trial, this plan recent antipsychotic trial, exposures is then miricorilant of the higher gain. the induced In in achieve examining GRATITUDE we we significantly the of will reversal which in test to again, formulation weight that miricorilant will
Finally, double both patients with of models first patients. NASH, to plan we quarter precursors blind miricorilant serious liver a and are of placebo-controlled liver affects reverses in miricorilant a the of fatty NASH. disorder of fibrosis start liver trial year, that which animal II and in prevents Phase next millions In
new more We potent also test intend miricorilant this our formulation of study. to in
had conclusion, profits. of and our an investments $XXX quarter to of Corcept balance and In We revenue outstanding increased million. cash first
We to relacorilant quarter had has with have pivotal Cushing's The in later GRACE, NDA two quarter. syndrome this the Cushing file planned. adrenal no now syndrome. treat originally patients III our our our debt. COVID-XX III quarters inside with relacorilant enrollment We than in of start Phase second in expect Phase trial XXXX, we trial GRADIENT, patients activation We to plan now of to slowed pandemic of
relacorilant trial with nab-paclitaxel half results to patients next We the first of our continue expect treat in cancer to of ovarian II Phase metastatic plus controlled of year.
called in sufficiently plus positive reliable RELIANT trial start pancreatic cancer. of we and nab-paclitaxel plan accelerated a results with metastatic quarter believe III support approval. patients relic Phase We This to relacorilant
relacorilant open to PD-X to plan adrenal check with an we study combined label treat metastatic with Ib quarter or unresectable Phase inhibitor patients start pembrolizumab cancer. Next
end year, of combination in by castration resistant suitable expect enzalutamide the advancement this we with to dose exicorilant Finally prostate of select for patients with cancer. to to treat
The caused positive results. Phase second has by reduce part earlier to gain miricorilant trial of olanzapine weight confirmed our Ib our
blind placebo-controlled is Phase gain double miricorilant Our of induced reduce II to weight open. trial antipsychotic recent
We antipsychotic We to as of We Phase the with improved resume miricorilant miricorilant. trial as in start quarter year-end an Phase plan by with trial standing miricorilant patients next our to health using in to long gain II a restrictions year. patients planned of plan in NASH public loosen. induced first originally now weight expect II formulation of enrollment start
stop questions. I'll here for
